At Karmanos we stand behind the statement - Better treatments. Better outcomes.
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are not available anywhere else. More than $60 million is invested each year into cancer research with a level of commitment and expertise that cannot be duplicated at local hospitals.
Maximally Effective Treatment
We believe that our total focus on cancer ensures we will always be the best in developing and applying maximally effective treatment options. Our energy and resources are never diverted to other pursuits.
Learn more about research at Karmanos
Karmanos Grand Rounds
The principal objective of the Karmanos Grand Rounds is to update cancer researchers and physicians on recent advances in the prevention, detection and treatment of cancer.
- Junior Investigators are encouraged to apply for an American Cancer Society Institutional Research Grant. Click here for more information.
Recent Research Accomplishments
- Karmanos is scheduled to receive more than $13 million in National Cancer Institute core grant support from December 2010 to November 2015, a 10 percent increase in research funds as compared to most other cancer centers.
- The award of a five-year, $9 million grant for Ann Schwartz, Ph.D., M.P.H., executive vice president of research and academic affairs, to support her INHALE study, which looks at the links between smoking, inflammation and the development of lung cancer.
- Dr. Venuprasad Poojary, Assistant Professor in the Department of Oncology at Wayne State University and Scientific Member of the Tumor and Microenvironment Program at Karmanos Cancer Institute, successfully secured a American Cancer Society grant for his research proposal entitled ‘Ubiquitin-mediated regulation of Tak1 and tumor-associated inflammation.”
- The appointment of Patricia LoRusso, D.O., director of Phase I Clinical Trials and the Eisenberg Center for Experimental Therapeutics at Karmanos, as co-leader of the Stand Up To Cancer and Melanoma Research Alliance Melanoma Dream Team.